Cumberland Pharmaceuticals Inc. announced it has launched its national U.S. sales promotion for Talicia and has assumed responsibility for the brand’s U.S. distribution and sales promotion under a co-commercialization agreement with RedHill Biopharma. The company said it will use its existing field sales force and additional marketing initiatives to increase awareness among gastroenterologists and other prescribing physicians. Cumberland also noted Talicia is patent protected through 2042 and received eight years of U.S. market exclusivity under its Qualified Infectious Disease Product designation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief on February 25, 2026, and is solely responsible for the information contained therein.